• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Researchers develop targeted, photodynamic nanoparticles for tumor therapy

December 6, 2016 By Sarah Faulkner

Researchers develop targeted, photodynamic nanoparticles for tumor therapyResearchers at the University of Massachusetts Medical School have developed photodynamic nanoparticles that can effectively target deep-tissue tumors. The team’s work was published in the Journal of the American Chemical Society. 

“This study signals a major step forward in photodynamic therapy by developing a new class of NIR-absorbing biodegradable organic nanoparticles for a highly effective targeting and treatment of deep-tissue tumors,” lead researcher Gang Han said in prepared remarks.

Photodynamic therapy involves dosing a patient with nontoxic light-sensitive drugs, which are absorbed by the body’s cells. A red laser light is then turned on to target the area of the body with a tumor. When the high power laser interacts with the light-sensitive drug, it forms a reactive form of oxygen that can kill malignant cancer cells and leave neighboring cells alone. But tissue penetration depth remains a challenge in photodynamic therapy.

The team of UMass researchers said they have found a way to make the process simpler and more efficient, penetrating further into the tumor tissue.

Han’s team encapsulated carbazole-substituted BODIPY molecules with biodegradable polymers, which then formed small, uniform nanoparticles. With incoherent lamp light, the photodynamic molecules can be tracked throughout the body and deep into the tissue to kill cancerous tumors. The team also reported that the nanoparticles had a long circulating time and could be removed from the body.

The molecules’ properties make them “sufficient to monitor and trigger practical photodynamic therapy effect of these nanoparticles within a wide variety of deep-tissue level tumors such as lung, colon, prostate and breast cancers,” Han said.

The team also suggested that because their method uses a low power lamp light, the method could provide opportunities for precise tumor-targeting theranostics in resource deficient areas.

Filed Under: Featured, Nanoparticles, Oncology, Research & Development Tagged With: University of Massachusetts

IN CASE YOU MISSED IT

  • Rapid Dose closes first tranche of $5M financing
  • Senseonics stock is up as it sticks by revenue guidance
  • MedAlliance wins second FDA IDE nod for drug-coated balloon
  • Wells Fargo downgrades Tandem amid rise of automated insulin delivery competition
  • FDA approves first targeted infusion therapy for HER2-low breast cancer

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS